Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. In addition, the company is developing BAN2401, which has completed Phase II clinical trial for the treatment of Alzheimer's disease, as well as Elenbecestat that is in Phase III clinical trial for treatment of early Alzheimer's disease. The company's Phase II clinical trial products comprise Opicinumab for MS; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild Alzheimer's disease. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BIIB
Previous Symbol
CUSIP09062X10
Phone617-679-2000
Debt
Debt-to-Equity Ratio0.43
Current Ratio2.75
Quick Ratio2.46
Price-To-Earnings
Trailing P/E Ratio13.16
Forward P/E Ratio12.37
P/E Growth1.24
Sales & Book Value
Annual Sales$12.27 billion
Price / Sales5.26
Cash Flow$26.8799 per share
Price / Cash Flow11.91
Book Value$59.56 per share
Price / Book5.38
Profitability
EPS (Most Recent Fiscal Year)$21.81
Net Income$2.54 billion
Net Margins24.08%
Return on Equity38.70%
Return on Assets20.54%
Miscellaneous
Employees7,300
Outstanding Shares201,480,000
Market Cap$65.00 billion
OptionableOptionable
Biogen (NASDAQ:BIIB) Frequently Asked Questions
What is Biogen's stock symbol?
Biogen trades on the NASDAQ under the ticker symbol "BIIB."
How were Biogen's earnings last quarter?
Biogen Inc (NASDAQ:BIIB) posted its earnings results on Tuesday, October, 23rd. The biotechnology company reported $7.40 earnings per share for the quarter, topping analysts' consensus estimates of $6.78 by $0.62. The biotechnology company had revenue of $3.44 billion for the quarter, compared to analysts' expectations of $3.33 billion. Biogen had a net margin of 24.08% and a return on equity of 38.70%. The company's revenue was up 11.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.31 earnings per share. View Biogen's Earnings History.
When is Biogen's next earnings date?
How can I listen to Biogen's earnings call?
Biogen will be holding an earnings conference call on Tuesday, January 29th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
What price target have analysts set for BIIB?
28 equities research analysts have issued 1-year target prices for Biogen's shares. Their forecasts range from $262.15 to $470.00. On average, they anticipate Biogen's share price to reach $382.5827 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price. View Analyst Price Targets for Biogen.
What is the consensus analysts' recommendation for Biogen?
28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 7 hold ratings and 21 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biogen.
What are Wall Street analysts saying about Biogen stock?
Here are some recent quotes from research analysts about Biogen stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $400 12-month price target. Biogen hosted a webcast this morning to outline its strategy in multiple sclerosis (MS), focusing on the pipeline as well as lifecycle management for the $9B base business. We saw detailed commentary about specific lifecycle management plans as most important. We think BIIB098 could be another option for new patients or Tecfidera switches. Although investors remain focused on aducanumab, we think understanding long-term MS growth is of similar importance." (12/12/2018)
- 2. Mizuho analysts commented, "We updated our model post the 2Q18 earnings call and BAN2401 data last week." (7/31/2018)
- 3. HC Wainwright analysts commented, "Valuation and risks. Our PT of $363/share is based on a discounted cash flow analysis using a 10% discount rate and 2.5% growth rate, in line with the expected discount and growth parameters of a commercial multiproduct biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing." (7/9/2018)
Has Biogen been receiving favorable news coverage?
Headlines about BIIB stock have trended somewhat negative recently, according to InfoTrie. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biogen earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Who are some of Biogen's key competitors?
Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), bluebird bio (BLUE), Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Halozyme Therapeutics (HALO) and Acceleron Pharma (XLRN).
Who are Biogen's key executives?
Biogen's management team includes the folowing people:
- Mr. Michel Vounatsos, CEO & Director (Age 56)
- Mr. Jeffrey D. Capello, Exec. VP & CFO (Age 53)
- Ms. Susan H. Alexander, Exec. VP, Chief of Legal & Corp. Services and Corp. Sec. (Age 61)
- Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 49)
- Dr. Paul F. McKenzie, Exec. VP of Pharmaceutical Operations & Technology (Age 52)
Who are Biogen's major shareholders?
Biogen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.19%), Primecap Management Co. CA (7.38%), Vanguard Group Inc. (7.35%), Vanguard Group Inc (7.35%), Clearbridge Investments LLC (4.39%) and FMR LLC (2.15%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.
Which major investors are selling Biogen stock?
BIIB stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, Morgan Stanley, Alliancebernstein L.P., Clearbridge Investments LLC, BlackRock Inc., Vanguard Group Inc. and Vanguard Group Inc. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, Michael D Ehlers and Robert W Pangia. View Insider Buying and Selling for Biogen.
Which major investors are buying Biogen stock?
BIIB stock was bought by a variety of institutional investors in the last quarter, including Capital World Investors, MERIAN GLOBAL INVESTORS UK Ltd, Renaissance Technologies LLC, American Century Companies Inc., Putnam Investments LLC, Canada Pension Plan Investment Board, Mackenzie Financial Corp and Rehmann Capital Advisory Group. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.
How do I buy shares of Biogen?
Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biogen's stock price today?
One share of BIIB stock can currently be purchased for approximately $320.14.
How big of a company is Biogen?
Biogen has a market capitalization of $64.43 billion and generates $12.27 billion in revenue each year. The biotechnology company earns $2.54 billion in net income (profit) each year or $21.81 on an earnings per share basis. Biogen employs 7,300 workers across the globe.
What is Biogen's official website?
How can I contact Biogen?
Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000.
MarketBeat Community Rating for Biogen (NASDAQ BIIB)
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
